Circulation

Vol. 153, Issue 25 Issue 25 2026
25
Articles

Articles in this Issue

Eugene Braunwald, MD, 1929–2026

James A. de Lemos, Joseph A. Hill Jun 23, 2026 pp. 1943-1943 10.1161/cir.0000000000001467

Beyond the Beats: The ECG Tells More Than We Think

Shasha Yu, Hang Lv, Ming Liu Jun 23, 2026 pp. 2097-2099 10.1161/circulationaha.126.079388

ALTO EN IMPACTO: Dr Guido Girardi and Chile’s Food Labeling Law: A Conversation With Guido Girardi, MD, MPH

Vanessa Blumer, Maryjane Farr Jun 23, 2026 pp. 1952-1959 10.1161/circulationaha.126.081616

Interventional MRI-Guided Ablation of Left Ventricular Tachycardia

Luuk H.G.A. Hopman, Marco J.W. Götte, Jules L. Nelissen et al. Jun 23, 2026 pp. 2106-2109 10.1161/circulationaha.126.080380

Lipoprotein(a) in High-Risk Primary Prevention: Making the Best of What We Have

Erin D. Michos, Roger S. Blumenthal Jun 23, 2026 pp. 1969-1972 10.1161/circulationaha.126.081436

In Memoriam, Eugene Braunwald, MD: The Gift That Keeps on Giving

Marc A. Pfeffer Jun 23, 2026 pp. 1944-1948 10.1161/circulationaha.126.081441

Breaking the Anchor: Overcoming Diagnostic Bias in Overlapping Cardiac Pathologies

Jonathan E. Labin, Andres E. Carmona-Rubio, Joseph Liu et al. Jun 23, 2026 pp. 2091-2096 10.1161/circulationaha.126.080604

Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial

Sebastiaan Dhont, Sara Moura Ferreira, Xavier Galloo et al. Jun 23, 2026 pp. 1973-1983 10.1161/circulationaha.126.080833

BACKGROUND: Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsart...

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients

Rick B. Vega, Gavin O’Mahony, April M. Barbour et al. Jun 23, 2026 pp. 1999-2010 10.1161/circulationaha.125.075973

BACKGROUND: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults wit...

A Slow Regular Rhythm After TAVR: A Clinical Reasoning Exercise

Sittinun Thangjui, Thirath Chatlaong, Jakrin Kewcharoen Jun 23, 2026 pp. 2102-2105 10.1161/circulationaha.126.081208

Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial

Pavel Osmancik, Petr Neuzil, Jana Hozmanova et al. Jun 23, 2026 pp. 1984-1998 10.1161/circulationaha.126.079484

BACKGROUND: Catheter ablation for atrial fibrillation (AF) is one of the most common cardiovascular procedures being performed worldwide. Despite the large body of evidence of its...

One Block, Two Block, or More? Keep Counting

Angkawipa Trongtorsak, Pranav Mankad, Kenneth A. Ellenbogen Jun 23, 2026 pp. 2100-2101 10.1161/circulationaha.126.081101

Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis

Meraj Neyazi, Gabriela Venturini, Kemar J. Brown et al. Jun 23, 2026 pp. 2011-2028 10.1161/circulationaha.126.079304

BACKGROUND: Cardiac sarcoidosis (CS) is an enigmatic disorder characterized by unexplained patchy, sterile granulomas intermixed with preserved myocardium and fibrotic regions with...

Observational Comparative Research in Cardiovascular and Brain Health and Disease: A Scientific Statement From the American Heart Association

Brian Mac Grory, Robert W. Yeh, Joshua A. Beckman et al. Jun 23, 2026 10.1161/cir.0000000000001440

Resources for observational comparative research have expanded enormously in recent years to include very large sources of granular, routinely collected health care data and modern statistical, epidem...

Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells

Lu Ren, Nadjet Belbachir, Hao Zhang et al. Jun 23, 2026 pp. 2110-2113 10.1161/circulationaha.125.076669

Under Pressure: A Rare Cause of Circulatory Collapse

Shamin Hayat Mahmud, Zachary Chroust, Ian J. Neeland Jun 23, 2026 pp. 2084-2090 10.1161/circulationaha.126.079491

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Roger S. Blumenthal, Pamela B. Morris, Mario Gaudino et al. Jun 23, 2026 10.1161/cir.0000000000001457

Farewell With Gratitude and Looking Ahead

Joseph A. Hill, James A. de Lemos Jun 23, 2026 pp. 1941-1942 10.1161/circulationaha.126.081053

Sam68 Exacerbates Pathologic Cardiac Hypertrophy by Suppressing Cardiomyocyte Glucose Oxidation

Junqing An, Chaoshan Han, Ying Jiang et al. Jun 23, 2026 pp. 2044-2063 10.1161/circulationaha.125.077533

BACKGROUND: Metabolic remodeling, marked by maladaptive shifts in substrate use and energy production, is a hallmark of pathologic cardiac hypertrophy. Yet t...

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial

Victorien Monguillon, Nicholas A. Marston, Erin A. Bohula et al. Jun 23, 2026 pp. 1960-1968 10.1161/circulationaha.126.080999

BACKGROUND: Lp(a) (lipoprotein[a]) is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher-risk patients who derive more benefit from evolocumab is no...

JNK2 Is a Stress Integrator Driving Atrial Fibrillation Pathogenesis in Aging via Gut-Heart Crosstalk

Jiajie Yan, Elena Carrillo, Aaryan Kohli et al. Jun 23, 2026 pp. 2029-2043 10.1161/circulationaha.125.076147

BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia and is associated with high morbidity and mortality, particularly in the aging population....

Challenges and Future Trends in Large Vessel Vasculitis

Maria Sandovici, Kornelis S.M. van der Geest, Rosanne D. Reitsema et al. Jun 23, 2026 pp. 2064-2083 10.1161/circulationaha.125.077491

Based on the Chapel Hill consensus criteria, the primary forms of vasculitis are classified by the predominant size of the affected blood vessels into large, medium, or small vessels. The two main for...

Secondary Prevention After Coronary Artery Bypass Graft Surgery: 2026 Update: A Scientific Statement From the American Heart Association

Marc Ruel, Sigrid Sandner, Menaka Ponnambalam et al. Jun 23, 2026 10.1161/cir.0000000000001434

Coronary artery bypass grafting is a well-established, durable, and safe surgical intervention. However, coronary artery disease continues to progress after the procedure. Patients who have undergone...

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis

Robert Przybylski, Gabrielle Norrish, Brian Claggett et al. Jun 23, 2026 10.1161/cir.0000000000001460

Why We Must Rethink Universal Lp(a) Screening as a Routine Cardiovascular Prevention Strategy

Degang Mo, Hongyan Dai Jun 23, 2026 pp. 1949-1951 10.1161/circulationaha.125.078939

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0009-7322
E-ISSN 1524-4539
Subject Health Sciences
Language English
View Full Journal Page